Steven Kanner
Chief Tech/Sci/R&D Officer bij CARIBOU BIOSCIENCES, INC.
Vermogen: 2 M $ op 31-03-2024
Profiel
Steven B.
Kanner is currently an Independent Director at Specific Biologics, Inc. since 2023 and the Chief Scientific Officer at Caribou Biosciences, Inc. since 2017.
Previously, he worked as the Vice President & Head-Biology at Arrowhead Pharmaceuticals, Inc. from 2013 to 2017.
He completed his undergraduate degree at the University of California, Berkeley and obtained doctorate degrees from the University of Miami and The University of Miami Leonard M.
Miller School of Medicine.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
20-02-2024 | 387 037 ( 0.43% ) | 2 M $ | 31-03-2024 |
Actieve functies van Steven Kanner
Bedrijven | Functie | Begin |
---|---|---|
CARIBOU BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 01-06-2017 |
Specific Biologics, Inc.
Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Director/Board Member | 10-10-2023 |
Eerdere bekende functies van Steven Kanner
Bedrijven | Functie | Einde |
---|---|---|
ARROWHEAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-06-2017 |
Opleiding van Steven Kanner
University of California, Berkeley | Undergraduate Degree |
The University of Miami Leonard M. Miller School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
CARIBOU BIOSCIENCES, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Specific Biologics, Inc.
Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Commercial Services |